

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-59) FROVOCIMAB

PRONUNCIATION froe vok' i mab

THERAPEUTIC CLAIM Treatment of hypercholesterolemia

## CHEMICAL NAMES

1. Immunoglobulin G4, anti-(proprotein convertase subtilisin kexin 9(PCSK9))(human monoclonal LY3015014  $\gamma$ 4-chain), disulfide with human monoclonal LY3015014 light-chain, dimer
2. Immunoglobulin G4-kappa, anti-(human proprotein convertase subtilisin/kexin type 9 (neural apoptosis-regulated convertase 1, proprotein convertase 9, subtilisin/kexin-like protease PC9, EC=3.4.21.-)); humanized monoclonal antibody;  $\gamma$ 4 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV3-21\*01 (89%) –(IGHD)-IGHJ4\*01 [8.8.18] (1-125) -*Homo sapiens* IGHG4\*01 {H S<sup>10</sup>>P(233), CH2 F<sup>4</sup>>A(239),L<sup>5</sup>>A(240), CH3 K<sup>107</sup>>-(del)} (126-451)] (139-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-28\*01 (87%) –IGKJ1\*01 [11.3.9] (1'-112') -*Homo sapiens* IGKC\*01 (113'-219')], dimer (231-231":234-234")-bisdisulfide

## STRUCTURAL FORMULA

### Heavy chain

EVQLVESGGG	LVKPGGSLRL	SCAASGFPFS	KLGMVWVWVRA	PGKLEWVST	50
ISSGGGYTY	PDSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCAREG	100
ISFQGGTYTY	VMDYWGQGT	VTVSSASTKG	PSVFLAPCS	RSTSESTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVTVPS	200
LGTKTYTCNV	DHKPSNTKVD	KRVESKYGPP	CPPCPAPEAA	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSQEDPEVQF	NWYVDGVEVH	NAKTKPREEQ	300
FNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KGLPSSIEKT	ISKAKGQPRE	350
PQVYTLPPSQ	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTP	400
PVLDSDSGFF	LYSRLTVDKS	RWQEGNVFSC	SVMHEALHNS	YTQKSLSLSL	450
G					451

### Light chain

DIVMTQSPLS	LPVTPGEPAS	ISCRSSKSL	HRNGITYSYW	YLQKPGQSPQ	50'
LLIYQLSNLA	SGVPDFRFGS	GSPTDFTLKI	SRVEAEDVGV	YCYQNLELP	100'
LPFGQGTQVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPREAK	150'
VQWKVDNALQ	SGNSQESVTE	QDSKDSSTYS	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

### Disulfide bridges

22-96	22"-96"	23'-93'	23""-93""	139'-199'	139""-199""	139-219'	139"-219""
152-208	152"-208"	231-231"	234-234"	266-326	266"-326"	372-430	372"-430"

### Glycosylation sites (N)

Asn-302 Asn-302'

MOLECULAR FORMULA  $C_{6506}H_{10062}N_{1718}O_{2036}S_{46}$  (nonglycosylated)

MOLECULAR WEIGHT 146.4 kDa (nonglycosylated)

TRADEMARK	None as yet
SPONSOR	Eli Lilly and Company
CODE DESIGNATIONS	LY3015014
<u>CAS</u> REGISTRY NUMBER	1643672-70-1
UNII	87PZ955YRB
WHO NUMBER	10859

gbk